Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation

被引:4
|
作者
Lin, Shin-Yi [1 ,2 ]
Kuo, Ching-Hua [2 ]
Ho, Li-Ting [3 ,4 ]
Liu, Yen-Bin [3 ,4 ]
Huang, Chih-Fen [1 ,2 ]
Tang, Sung-Chun [5 ,6 ]
Jeng, Jiann-Shing [5 ,6 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Cardiovasc Ctr, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan
关键词
atrial fibrillation; edoxaban; factor Xa inhibitors; therapeutic drug monitoring; Asians; PREDICTING STROKE; PHARMACODYNAMICS; PHARMACOKINETICS; ANTICOAGULANT; WARFARIN; OUTCOMES; RISK;
D O I
10.3389/fphar.2021.736826
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations. Methods: Participants with atrial fibrillation who were undergoing edoxaban therapy were enrolled. Peak (1-4 h after edoxaban administration) and trough (24 +/- 4 h from the last edoxaban dose) blood samples were collected to measure edoxaban concentrations using ultrahigh-performance liquid chromatography with tandem mass spectrometry. The edoxaban concentrations were compared to those observed in clinical trials to define a higher- or lower-than-expected range. Multivariate logistic regression was used to analyze the risk factors associated with high or low edoxaban concentrations. Results: Eighty participants (49 men, 61.3%) were enrolled and provided 78 trough and 76 peak samples. Twenty participants (25.6%) were determined to have low trough concentrations, which was associated with higher creatinine clearance and the use of the 30 mg regimen (odds ratio [OR] and 95% confidence interval [CI], 1.06 [1.01, 1.11], p = 0.01 and 5.77 [1.34, 24.75], p = 0.02, respectively). In contrast, 21 participants (27.6%) had high peak concentrations, which was associated with an off-label overdosing regimen (OR = 4.68 [1.23, 17.70], p = 0.02). Conclusion: Our study identified factors associated with increased or decreased edoxaban exposure. The measurement of edoxaban concentration may be recommended for patients with selected characteristics.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence
    Cay, Serkan
    Kasap, Mithat
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2023, 51 (08): : 565 - 573
  • [22] Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation
    Yamashita, Takeshi
    Koretsune, Yukihiro
    Yasaka, Masahiro
    Inoue, Hiroshi
    Kawai, Yohko
    Yamaguchi, Takenori
    Uchiyama, Shinichiro
    Matsumoto, Masayasu
    Ogawa, Satoshi
    CIRCULATION JOURNAL, 2012, 76 (08) : 1840 - 1847
  • [23] Edoxaban versus Warfarin in Patients with Atrial Fibrillation
    Giugliano, Robert P.
    Ruff, Christian T.
    Braunwald, Eugene
    Murphy, Sabina A.
    Wiviott, Stephen D.
    Halperin, Jonathan L.
    Waldo, Albert L.
    Ezekowitz, Michael D.
    Weitz, Jeffrey I.
    Spinar, Jindrich
    Ruzyllo, Witold
    Ruda, Mikhail
    Koretsune, Yukihiro
    Betcher, Joshua
    Shi, Minggao
    Grip, Laura T.
    Patel, Shirali P.
    Patel, Indravadan
    Hanyok, James J.
    Mercuri, Michele
    Vogelmann, O.
    Gonzalez, C.
    Ahuad Guerrero, R.
    Rodriguez, M.
    Albisu, J.
    Rosales, E.
    Allall, O.
    Reguero, M.
    Alvarez, C.
    Garcia, M.
    Ameriso, S.
    Ameriso, P.
    Amuchastegui, M.
    Caceres, M.
    Beloscar, J.
    Petrucci, J.
    Berli, M.
    Budassi, N.
    Valle, M.
    Bustamante Labarta, G.
    Saravia, M.
    Caccavo, A.
    Fracaro, V.
    Cartasegna, L.
    Novas, V.
    Caruso, O.
    Saa Zarandon, R.
    Colombo, H.
    Morandini, M.
    Cuello, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22) : 2093 - 2104
  • [24] Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure
    Aspromonte, Nadia
    Colivicchi, Furio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (01) : 113 - 122
  • [25] Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program
    Chao, Tze-Fan
    Hong, Keun-Sik
    Lee, Byung-Chul
    De Caterina, Raffaele
    Kirchhof, Paulus
    Reimitz, Paul-Egbert
    Chen, Cathy
    Unverdorben, Martin
    Wang, Chun-Chieh
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2021, 84 (05) : 485 - 490
  • [26] Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
    Nabeta, Takeru
    Kida, Keisuke
    Ishida, Miwa
    Shiono, Takaaki
    Suzuki, Norio
    Doi, Shunichi
    Tsukahara, Maya
    Ohta, Yuki
    Kimura, Tetsuya
    Yamaguchi, Keita
    Takita, Atsushi
    Matsumoto, Naoki
    Akashi, Yoshihiro J.
    Ako, Junya
    Inomata, Takayuki
    CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1061 - 1071
  • [27] Edoxaban: A Review in Nonvalvular Atrial Fibrillation
    McCormack, Paul L.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2015, 15 (05) : 351 - 361
  • [28] How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy
    Yin, Yi-wei
    Liu, Xiao-qin
    Gu, Jia-qin
    Li, Zi-ran
    Jiao, Zheng
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (07) : 2066 - 2075
  • [29] Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
    Mikami, Ryusei
    Hayakawa, Mineji
    Imai, Shungo
    Maekawa, Kunihiko
    Yamazaki, Kojiro
    Sugawara, Mitsuru
    Takekuma, Yoh
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [30] Gastrointestinal Bleeding From Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA Atrial Fibrillation Registry
    Murata, Nobuhiro
    Okumura, Yasuo
    Nagashima, Koichi
    Fukamachi, Daisuke
    Yokoyama, Katsuaki
    Matsumoto, Naoya
    Tachibana, Eizo
    Kuronuma, Keiichiro
    Oiwa, Koji
    Matsumoto, Michiaki
    Kojima, Toshiaki
    Hanada, Shoji
    Nomoto, Kazumiki
    Arima, Ken
    Takahashi, Fumiyuki
    Kotani, Tomobumi
    Ikeya, Yukitoshi
    Fukushima, Seiji
    Itou, Satoru
    Kondo, Kunio
    Chiku, Masaaki
    Ohno, Yasumi
    Onikura, Motoyuki
    Hirayama, Atsushi
    CIRCULATION JOURNAL, 2020, 84 (09) : 1475 - 1482